FS-1502 in HER2-positive advanced breast cancer: Results from an open-label, phase 1 study.

被引：0
|
作者：
Li, Qiao
Cheng, Ying
Tong, Zhongsheng
Liu, Yunjiang
Wang, Xian
Yan, Min
Chang, Jianhua
Wang, Shusen
Du, Caiwen
Li, Liang
Wu, Chunjiao
Wang, Mingxia
Wang, Zhuo
Wu, Zhuli
Jin, Yongli
Zhang, Yongjiao
Hui, Ai-Min
Wang, Xingli
Xu, Binghe
机构：
[1] Chinese Acad Med Sci, Dept Med Oncol, Canc Hosp, Beijing, Peoples R China
[2] Jilin Canc Hosp, Dept Oncol, Changchun, Peoples R China
[3] Tianjin Med Univ Canc Inst & Hosp, Dept Breast Oncol, Tianjin, Peoples R China
[4] Hebei Med Univ, Dept Breast Ctr, Hosp 4, Shijiazhuang, Hebei, Peoples R China
[5] Zhejiang Univ, Sir Run Run Shaw Hosp, Dept Med Oncol, Sch Med, Hangzhou, Zhejiang, Peoples R China
[6] Zhengzhou Univ, Dept Breast Dis, Henan Breast Canc Ctr, Affiliated Canc Hosp, Zhengzhou, Peoples R China
[7] Henan Canc Hosp, Zhengzhou, Peoples R China
[8] Chinese Acad Med Sci, Shenzhen Ctr, Dept Med Oncol, Canc Hosp, Shenzhen, Peoples R China
[9] Sun Yat Sen Univ, Canc Ctr, Guangzhou, Guangdong, Peoples R China
[10] Meizhou Peoples Hosp, Dept Med Oncol, Meizhou, Guangdong, Peoples R China
[11] Jilin Canc Hosp, Dept Oncol, Phase ward 1, Changchun, Jilin, Peoples R China
[12] Hebei Med Univ, Dept Phase 1, Clin Trial Unit, Hosp 4, Shijiahuang, Hebei, Peoples R China
[13] Beijing Fosun Pharmaceut Res & Dev Co Ltd, Shanghai, Peoples R China
[14] Fosun Pharma USA Inc, Lexington, MA USA
[15] Shanghai Fosun Pharmaceut Dev Co Ltd, Shanghai, Peoples R China
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2023年 / 41卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
3044
引用
收藏
页数：1
相关论文
共 50 条
  • [11] MOUNTAINEER: Open-label, phase II study of tucatinib combined with trastuzumab for HER2-positive metastatic colorectal cancer
    Strickler, J.
    Ng, K.
    Cercek, A.
    Fountzilas, C.
    Sanchez, F.
    Hubbard, J.
    Wu, C.
    Stecher, M.
    Walker, L. N.
    Bekaii-Saab, T.
    ANNALS OF ONCOLOGY, 2020, 31 : S460 - S461
  • [12] An open-label, multicenter, phase Ib study to evaluate RC48-ADC in patients with HER2-positive metastatic breast cancer
    Xu, Binghe
    Wang, Jiayu
    Zhang, Qingyuan
    Liu, Yunjiang
    Feng, Ji Feng
    Wang, Wenxiang
    Fang, Jianmin
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [13] Assessment of safety and tolerability of Herceptin subcutaneous administration in patients with HER2-positive early breast cancer: results of an open-label, randomized, multicenter, phase IIIB study
    Talayeva, S.
    Kaidarova, D.
    Zhavrid, E.
    Prokharau, A.
    Antonenkova, N.
    Shatkovskaya, O.
    Manasheva, A.
    Rutzhanova, Z.
    BREAST, 2017, 32 : S27 - S27
  • [14] HER2-positive advanced breast cancer
    Robert, Nicholas J.
    Favret, Anne M.
    HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA, 2007, 21 (02) : 293 - +
  • [15] Results From the First Multicenter, Open-label, Phase IIIb Study Investigating the Combination of Pertuzumab With Subcutaneous Trastuzumab and a Taxane in Patients With HER2-positive Metastatic Breast Cancer (SAPPHIRE)
    Woodward, Natasha
    De Boer, Richard H.
    Redfern, Andrew
    White, Michelle
    Young, Jennifer
    Truman, Matt
    Beith, Jane
    CLINICAL BREAST CANCER, 2019, 19 (03) : 216 - 224
  • [16] HER2-targeting antibody drug conjugate FS-1502 in HER2-expressing metastatic breast cancer: a phase 1a/1b trial
    Li, Qiao
    Cheng, Ying
    Tong, Zhongsheng
    Liu, Yunjiang
    Wang, Xian
    Yan, Min
    Chang, Jianhua
    Wang, Shusen
    Du, Caiwen
    Li, Liang
    Wu, Chunjiao
    Wang, Mingxia
    Wang, Zhuo
    Wu, Zhuli
    Wang, Xingli
    Jin, Yongli
    Diao, Lei
    Sun, Yi
    Zhang, Yongjiao
    Hui, Ai-Min
    Xu, Binghe
    NATURE COMMUNICATIONS, 2024, 15 (01)
  • [17] FS-1502, an anti-HER2 ADC, in Patients with HER2-Expressing Advanced Solid Tumors: A Phase 1a Dose-Escalation Study
    Li, Qiao
    Wang, Xian
    Cheng, Ying
    Liu, Yunjiang
    Chang, Jianhua
    Wang, Zhuo
    Wu, Chunjiao
    Wang, Mingxia
    Hui, Ai-Min
    Wu, Zhuli
    Jin, Yongli
    Huang, Xin
    Zhong, Liping
    Diao, Lei
    Zhao, Han
    Xu, Binghe
    CANCER RESEARCH, 2023, 83 (05)
  • [18] A Neoadjuvant, Randomized, Open-Label Phase II Trial of Afatinib Versus Trastuzumab Versus Lapatinib in Patients With Locally Advanced HER2-Positive Breast Cancer
    Rimawi, Mothaffar F.
    Aleixo, Sabina B.
    Alarcon Rozas, Ashley
    de Matos Neto, Joao Nunes
    Caleffi, Maira
    Figueira, Alicardo Cesar
    Souza, Sulene Cunha
    Reiriz, Andre B.
    Gutierrez, Carolina
    Arantes, Heloisa
    Uttenreuther-Fischer, Martina M.
    Solca, Flavio
    Osborne, C. Kent
    CLINICAL BREAST CANCER, 2015, 15 (02) : 101 - 109
  • [19] MetaPHER phase IIIb multicenter, open-label, single-arm safety study of subcutaneous trastuzumab in combination with pertuzumab and docetaxel in patients with HER2-positive advanced breast cancer: First results
    Kuemmel, S.
    Abraham, J.
    Martin, M.
    Crepelle-Flechais, A.
    Swat, A.
    Nueesch, E.
    Shing, M.
    Tondini, C. A.
    CANCER RESEARCH, 2017, 77
  • [20] Trastuzumab plus docetaxel and capecitabine for first-line treatment of Her2-positive advanced gastric cancer: A phase II, multi-center, open-label, singlearm study.
    Wang, Feng
    Liu, Tian Shu
    Yuan, Xianglin
    Gu, Kangsheng
    Yuan, Ying
    Deng, Yanhong
    Xu, Jian-Ming
    Bai, Yu-Xian
    Wang, Ying
    Liao, Wangjun
    Zhang, He-Long
    Bi, Feng
    Wang, Bang-Mao
    Zhuang, Zhixiang
    Luo, Huiyan
    Xu, Rui-hua
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
12345